Search
Research
ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in childrenChris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear Health Clinical Research
Research
AuTOmatic: Adaptive Trial of MessAging to improve Immunisation CoverageTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@telethonkids.org.au Head,
Research
BEAT-CF: Bayesian Evidence-Adaptive Tool to optimise management of Cystic FibrosisStephen André Stick Schultz MB BChir PhD MRCP FRACP MBChB, PhD, FRACP Head, P4 Respiratory Health for Kids Program Head, Respiratory Health RFA Head
Research
Bright Tomorrows Start Today (Parent App)Our team: Karen Forde (Project Lead), Candice Rainsford (Project Coordinator), Aida Noordin (Research Assistant) and Joanne Readman (Project
Research
Characterising the development of molecular and hormonal circadian rhythm development in preterm infantsJane Pillow BMedSci (Dist) MBBS, PhD (Dist) FRACP Research Theme Head, Early Environment; Team Lead, Chronobiology jane.pillow@telethonkids.org.au
Research
Chemosensitisation of medulloblastoma and pineoblastomaRaelene Nick Endersby Gottardo BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research Co-Head, Brain Tumour Research
Research
Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of diseaseChristopher Deborah Hannah Lea-Ann Peter Blyth Lehmann Moore Kirkham Richmond MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc OAM BSc (Hons)
The CIRCA DIEM Study is a clinical research study being coordinated by the Chronobiology Team at Telethon Kids Institute, who are based in Perth, Western Australia and involving research teams from around the world.
Research
COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years oPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosisStephen Graham Stick Hall MB BChir PhD MRCP FRACP BAppSci PhD CRFS FANZSRS FThorSoc FERS Head, P4 Respiratory Health for Kids Honorary Research